Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00655486 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
A Phase 3 study of Partial Epilepsies and Partial-onset Seizures, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 97
- Enrollment target
- 7
- Study locations
NCT00655486 is a Phase 3 study of Partial Epilepsies and Partial-onset Seizures that has completed, run by UCB Biosciences. The registered enrollment target is 97 participants. The trial reports 7 study locations across 7 states.
The verdict
NCT00655486, a Phase 3 study of Partial Epilepsies and Partial-onset Seizures, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 97 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to allow eligible subjects from the parent study, SP925 \[NCT00655551\] to continue lacosamide and to obtain additional long-term safety data
Conditions Studied
Interventions
- DRUG lacosamide
Study Locations (7)
Arizona
- - Phoenix
Maryland
- - Baltimore
Missouri
- - Chesterfield
Ohio
- - Columbus
Pennsylvania
- - Philadelphia
Texas
- - Dallas
Virginia
- - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00655486
The ClinicalTrials.gov registry entry for NCT00655486 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Partial Epilepsies appearing as the primary indexed condition, and to 1 intervention - of which lacosamide is the first listed.
NCT00655486 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, Maryland, Missouri.
Frequently Asked Questions
What is clinical trial NCT00655486 about?
NCT00655486 is a clinical study titled "Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures". The purpose of this study is to allow eligible subjects from the parent study, SP925 \[NCT00655551\] to continue lacosamide and to obtain additional long-term safety data
What is the current status of trial NCT00655486?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 97 participants. The study started on 2008-04. Estimated completion is 2010-06.
What conditions does trial NCT00655486 study?
This clinical trial studies the following conditions: Partial Epilepsies, Partial-onset Seizures.
What interventions are being tested in trial NCT00655486?
The interventions under investigation include: lacosamide (DRUG).
Who is sponsoring clinical trial NCT00655486?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00655486 being conducted?
This trial has 7 study locations across Arizona, Maryland, Missouri, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Partial Epilepsies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.